Literature DB >> 11561747

Ureteric and pulmonary endometriosis.

M Ludwig1, O Bauer, G J Wiedemann, K Diedrich.   

Abstract

Pulmonary lesions and ureter involvement are rare complications of endometriosis. We describe the first case with an involvement of both sites in this condition. The radiographs showed "pulmonary metastases" together with clinical findings of a hydronephrosis, mimicing a malignant metastatic gynecologic tumor of unknown primary. A laparoscopy showed severe endometriotic lesions; therefore the findings were most likely related to the condition of endometriosis. The patient was treated with gosereline acetate for six months (Zoladex). Control radiographs showed complete regression of the pulmonary lesions and the patient is symptom free at 36 months after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561747     DOI: 10.1007/s004040100182

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  4 in total

Review 1.  Novel therapies targeting endometriosis.

Authors:  Hugh S Taylor; Kevin G Osteen; Kaylon L Bruner-Tran; Charles J Lockwood; Graciela Krikun; Anna Sokalska; Antoni J Duleba
Journal:  Reprod Sci       Date:  2011-06-21       Impact factor: 3.060

Review 2.  Synchronous rectovaginal, urinary bladder, and pulmonary endometriosis.

Authors:  Georgios E Hilaris; Christopher K Payne; Joelle Osias; Walter Cannon; Camran R Nezhat
Journal:  JSLS       Date:  2005 Jan-Mar       Impact factor: 2.172

3.  Cystoscopy-assisted laparoscopy for bladder endometriosis: modified light-to-light technique for bladder preservation.

Authors:  Rafael Mamprin Stopiglia; Ubirajara Ferreira; Daniel Gustavo Faundes; Carlos Alberto Petta
Journal:  Int Braz J Urol       Date:  2017 Jan-Feb       Impact factor: 1.541

4.  Isolated intraluminal ureteral endometriosis mimicking tuberculosis.

Authors:  S Rajaian; M Pragatheeswarane; K Krishnamurthy; S C Narasimhachar
Journal:  J Postgrad Med       Date:  2019 Jan-Mar       Impact factor: 1.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.